Biopharma companies secured $102.15 billion in funding in 2024, a 44% increase from $70.97 billion in the full-year 2023 and significantly higher than the $60.81 billion raised in 2022. December financings reached $4.69 billion, marking an increase from $3.6 billion in November.

Companies working in the field of women’s health have long struggled for funding, but as the number of these companies increase and new dedicated venture capital funds emerge, the conversation is changing.

Med-tech deals activity dropped significantly in 2024, falling 84% from $9.83 billion in the first nine months of 2023 to $1.6 billion in the same period this year. While down from $6.59 billion in Q1 to Q3 2022, value is higher than $979.84 million in the comparable period in 2021.

Med-tech companies raised $25.36 billion in financings in 2024, marking a 43% increase from $17.68 billion in 2023. December saw a significant rise, with $1.72 billion raised, compared to $919.99 million in November.

Despite a sometimes-turbulent stock market and over 18,000 job losses, 2024 closed with signs of recovery, marked by growth in both financings and deals, setting an optimistic tone for 2025.

As investors and industry alike try to read the tea leaves of what the upcoming change in administrations holds for the U.S., speculation abounds about what Trump 2.0 will mean for the biopharma and med-tech spaces.

Intriguing scientific data continue to roll out in the head and neck cancer space, where the need for therapies has spurred a number of drug firms to try new approaches, which BioWorld examines in part two of a series that began in the Dec. 30 issue.

From local drug discovery to global innovation, economic uncertainty is taking a toll on China’s innovative biotech system, forcing local companies to weather unpredictable storms, investors said during the Chinabio Partnering Forum in Shanghai in September.